To offer pragmatic, evidence-informed advice on administering corticosteroids in otolaryngology during the coronavirus disease 2019 (COVID-19) pandemic, considering therapeutic efficacy, potential adverse effects, susceptibility to COVID-19, and potential effects on efficacy of vaccination against SARS-CoV-2, which causes COVID-19.
Data Sources
PubMed, Cochrane Library, EMBASE, CINAHL, and guideline databases.
Review Methods
Guideline search strategies, supplemented by database searches on sudden sensorineural hearing loss (SSNHL), idiopathic facial nerve paralysis (Bell’s palsy), sinonasal polyposis, laryngotracheal disorders, head and neck oncology, and pediatric otolaryngology, prioritizing systematic reviews, randomized controlled trials, and COVID-19–specific findings.
Conclusions
Systemic corticosteroids (SCSs) reduce long-term morbidity in individuals with SSNHL and Bell’s palsy, reduce acute laryngotracheal edema, and have benefit in perioperative management for some procedures. Topical or locally injected corticosteroids are preferable for most other otolaryngologic indications. SCSs have not shown long-term benefit for sinonasal disorders. SCSs are not a contraindication to vaccination with COVID-19 vaccines approved by the US Food and Drug Administration. The Centers for Disease Control and Prevention noted that these vaccines are safe for immunocompromised patients.
Implications for Practice
SCS use for SSNHL, Bell’s palsy, laryngotracheal edema, and perioperative care should follow prepandemic standards. Local or topical corticosteroids are preferable for most other otolaryngologic indications. Whether SCSs attenuate response to vaccination against COVID-19 or increase susceptibility to SARS-CoV-2 infection is unknown. Immunosuppression may lower vaccine efficacy, so immunocompromised patients should adhere to recommended infection control practices. COVID-19 vaccination with Pfizer-BioNTech, Moderna, or Johnson & Johnson vaccines is safe for immunocompromised patients.
CopeDBovaR. Steroids in otolaryngology. Laryngoscope. 2008;118(9):1556-1560.
2.
HermanPVincentCParietti WinklerC, et al. Consensus statement: corticosteroid therapy in ENT in the context of the COVID-19 pandemic. Eur Ann Otorhinolaryngol Head Neck Dis. 2020;137(4):315-317.
3.
BaughRFBasuraGJIshiiLE, et al. Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck Surg. 2013;149(3):S1-S27.
4.
ChandrasekharSSTsai DoBSSchwartzSR, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. 2019;161(1):S1-S45.
5.
MacauleyPMartinAEpelbaumO. Corticosteroids in the treatment of severe COVID-19 lung disease: the pulmonology perspective from the first United States epicenter. Int J Infect Dis. 2020;100:309-313.
RussellCDMillarJEBaillieJK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473-475.
8.
Brun-BuissonCRichardJCMercatAThiebautACBrochardL; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(9):1200-1206.
9.
StockmanLJBellamyRGarnerP. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.
10.
ArabiYMMandourahYAl-HameedF, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767.
11.
LeeNAllen ChanKCHuiDS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-309.
12.
GroupRCHorbyPLimWS, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693-704.
13.
WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group; SterneJACMurthySDiazJV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341.
14.
PrescottHCRiceTW. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. JAMA. 2020;324(13):1292-1295.
PandianVBrodskyMBBrighamEP, et al. COVID-19 survivorship: how otolaryngologist–head and neck surgeons can restore quality of life after critical illness. Am J Otolaryngol. 2021;42(3):102917.
17.
LosorelliSDVendraVHildrewDMWoodsonEABrennerMJSirjaniDB. The future of telemedicine: revolutionizing health care or flash in the pan?Otolaryngol Head Neck Surg. 2021;165(2):239-243.
18.
Bier-LaningCCramerJDRoyS, et al. Tracheostomy during the COVID-19 pandemic: comparison of international perioperative care protocols and practices in 26 countries. Otolaryngol Head Neck Surg. 2021;164(6):1136-1147.
19.
RosenfeldRMPiccirilloJFChandrasekharSS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2):S1-S39.
20.
StachlerRJFrancisDOSchwartzSR, et al. Clinical practice guideline: hoarseness (dysphonia) (update). Otolaryngol Head Neck Surg. 2018;158(1):S1-S42.
21.
PynnonenMAGillespieMBRomanB, et al. Clinical practice guideline: evaluation of the neck mass in adults. Otolaryngol Head Neck Surg. 2017;157(2):S1-S30.
22.
AlexanderTHHarrisJP. Incidence of sudden sensorineural hearing loss. Otol Neurotol. 2013;34(9):1586-1589.
23.
BylFM. Seventy-six cases of presumed sudden hearing loss occurring in 1973: prognosis and incidence. Laryngoscope. 1977;87(5, pt 1):817-825.
24.
DallanIFortunatoSCasaniAP, et al. Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation. J Laryngol Otol. 2014;128(8):669-673.
25.
ChauJKLinJRAtashbandSIrvineRAWesterbergBD. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope. 2010;120(5):1011-1021.
26.
KuhnMHeman-AckahSEShaikhJARoehmPC. Sudden sensorineural hearing loss: a review of diagnosis, treatment, and prognosis. Trends Amplif. 2011;15(3):91-105.
27.
ChernAFamuyideAOMoonisGLalwaniAK. Sudden sensorineural hearing loss and COVID-19: an evolving discussion. Otol Neurotol. 2021;42(7):e968-e969.
28.
MahlCMeloLRSAlmeidaMHA, et al. Delay in head and neck cancer care during the COVID-19 pandemic and its impact on health outcomes. Braz Oral Res. 2020;34:e126.
29.
MaringeCSpicerJMorrisM, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21(8):1023-1034.
30.
RabboneISchiaffiniRCherubiniV, et al. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children?Diabetes Care. 2020;43(11):2870-2872.
31.
BarczikJSerpanosYC. Accuracy of smartphone self-hearing test applications across frequencies and earphone styles in adults. Am J Audiol. 2018;27(4):570-580.
32.
BrightTPallawelaD. Validated smartphone-based apps for ear and hearing assessments: a review. JMIR Rehabil Assist Technol. 2016;3(2):e13.
33.
CzeislerMEMarynakKClarkeKEN, et al. Delay or avoidance of medical care because of COVID-19–related concerns: United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(36):1250-1257.
34.
KilicOKalciogluMTCagY, et al. Could sudden sensorineural hearing loss be the sole manifestation of COVID-19? An investigation into SARS-CoV-2 in the etiology of sudden sensorineural hearing loss. Int J Infect Dis. 2020;97:208-211.
35.
HarenbergJJonasJBTreccaEMC. A liaison between sudden sensorineural hearing loss and SARS-CoV-2 infection. Thromb Haemost. 2020;120(9):1237-1239.
36.
ChernAFamuyideAOMoonisGLalwaniAK. Bilateral sudden sensorineural hearing loss and intralabyrinthine hemorrhage in a patient with COVID-19. Otol Neurotol. 2021;42(1):e10-e14.
37.
ChariDAParikhAKozinEDReedMJungDH. Impact of COVID-19 on presentation of sudden sensorineural hearing loss at a single institution. Otolaryngol Head Neck Surg. 2021;165(1):163-165.
38.
ElibolE. Otolaryngological symptoms in COVID-19. Eur Arch Otorhinolaryngol. 2021;278(4):1233-1236.
39.
Ozcelik KorkmazMEgilmezOKOzcelikMAGuvenM. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. Eur Arch Otorhinolaryngol. 2021;278(5):1675-1685.
40.
FreniFMeduriAGaziaF, et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): a possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol. 2020;41(5):102612.
41.
LangBHintzeJConlonB. Coronavirus disease 2019 and sudden sensorineural hearing loss. J Laryngol Otol. Published online October 1, 2020. doi:10.1017/S0022215120002145
42.
LamounierPFranco GoncalvesVRamosHVL, et al. A 67-year-old woman with sudden hearing loss associated with SARS-CoV-2 infection. Am J Case Rep. 2020;21:e927519.
43.
KoumpaFSFordeCTManjalyJG. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep. 2020;13(11):e238419.
44.
ChenCYHalpinCRauchSD. Oral steroid treatment of sudden sensorineural hearing loss: a ten year retrospective analysis. Otol Neurotol. 2003;24(5):728-733.
45.
LeongKJLauTStewartVCanettiEFD. Systematic review and meta-analysis: effectiveness of corticosteroids in treating adults with acute vestibular neuritis. Otolaryngol Head Neck Surg. 2021;165(2):255-266.
46.
NaroznyWSkorekATretiakowD. Does treatment of sudden sensorineural hearing loss in patients with COVID-19 require anticoagulants?Otolaryngol Head Neck Surg. 2021;165(1):236-237.
HohmanMHHadlockTA. Etiology, diagnosis, and management of facial palsy: 2000 patients at a facial nerve center. Laryngoscope. 2014;124(7):E283-E293.
49.
OTMJowettNHadlockTA. Facial palsy: diagnostic and therapeutic management. Otolaryngol Clin North Am. 2018;51(6):xvii-xviii.
50.
ZammitMMarkeyAWebbC. A rise in facial nerve palsies during the coronavirus disease 2019 pandemic. J Laryngol Otol. Published online October 1, 2020. doi:10.1017/S0022215120002121
51.
GronsethGSPadugaR, American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79(22):2209-2213.
52.
SullivanFMSwanIRDonnanPT, et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med. 2007;357(16):1598-1607.
53.
AxelssonSBergTJonssonLEngstromMKanervaMStjernquist-DesatnikA. Bell’s palsy—the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial. Clin Otolaryngol. 2012;37(4):283-290.
54.
LimaMASilvaMTTSoaresCN, et al. Peripheral facial nerve palsy associated with COVID-19. J Neurovirol. 2020;26(6):941-944.
55.
CodeluppiLVenturelliFRossiJ, et al. Facial palsy during the COVID-19 pandemic. Brain Behav. 2021;11(1):e01939.
US Food and Drug Administration. FDA briefing document: Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. Accessed March 24, 2021. https://www.fda.gov/media/146217/download
59.
OzonoffANanishiELevyO. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect Dis. 2021;21(4):450-452.
60.
ShemerAPrasEEinan-LifshitzADubinsky-PertzovBHechtI. Association of COVID-19 vaccination and facial nerve palsy: a case-control study. JAMA Otolaryngol Head Neck Surg. 2021;147(8):739-743.
61.
TamakiACabreraCILiS, et al. Incidence of Bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(8):767-768.
Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). WONDER database. Accessed March 24, 2021. http://wonder.cdc.gov/vaers.html
ChangCWD. Bell palsy and COVID-19: overcoming the fear of “known unknowns.”JAMA Otolaryngol Head Neck Surg. 2021;147(8):743-744.
67.
EscalanteDAMalkaREWilsonAG, et al. Determining the prognosis of Bell’s palsy based on severity at presentation and electroneuronography. Otolaryngol Head Neck Surg. Published March 30, 2021. doi:10.1177/01945998211004169
DiazRCCervenkaBBrodieHA. Treatment of temporal bone fractures. J Neurol Surg B Skull Base. 2016;77(5):419-429.
70.
ChangCYCassSP. Management of facial nerve injury due to temporal bone trauma. Am J Otol. 1999;20(1):96-114.
71.
ThakarAGuptaMPSrivastavaAAgrawalDKumarA. Nonsurgical treatment for posttraumatic complete facial nerve paralysis. JAMA Otolaryngol Head Neck Surg. 2018;144(4):315-321.
72.
SweissNJKorstenPSyedHJ, et al. When the game changes: guidance to adjust sarcoidosis management during the coronavirus disease 2019 pandemic. Chest. 2020;158(3):892-895.
PoetkerDM. Oral corticosteroids in the management of chronic rhinosinusitis with and without nasal polyps: risks and benefits. Am J Rhinol Allergy. 2015;29(5):339-342.
75.
KirtsreesakulVWongsritrangKRuttanapholS. Does oral prednisolone increase the efficacy of subsequent nasal steroids in treating nasal polyposis?Am J Rhinol Allergy. 2012;26(6):455-462.
76.
OrlandiRRKingdomTTHwangPH, et al. International consensus statement on allergy and rhinology: rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(suppl 1):S22-S209.
77.
ChangMTNoelJAyoubNF, et al. Oral corticosteroids following endoscopic sinus surgery for chronic rhinosinusitis without nasal polyposis: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2021;147(5):434-441.
78.
KlimekLJutelMBousquetJ, et al. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic—an EAACI position paper. Allergy. 2021;76(3):677-688.
79.
HowardJHuangALiZ, et al. An evidence review of face masks against COVID-19. Proc Natl Acad Sci U S A. 2021;118(4):e2014564118.
80.
PratherKAWangCCSchooleyRT. Reducing transmission of SARS-CoV-2. Science. 2020;368(6498):1422-1424.
81.
Van ZeleTGevaertPHoltappelsG, et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069-1076, e1064.
82.
BachertCHanJKDesrosiersM, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
83.
GoshtasbiKAbouzariMAbiriA, et al. Efficacy of steroid-eluting stents in management of chronic rhinosinusitis after endoscopic sinus surgery: updated meta-analysis. Int Forum Allergy Rhinol. 2019;9(12):1443-1450.
84.
LuongAOwRASinghA, et al. Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2018;144(1):28-35.
85.
RudmikLSmithTL. Economic evaluation of a steroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2014;151(2):359-366.
86.
SmithTLSinghALuongA, et al. Randomized controlled trial of a bioabsorbable steroid-releasing implant in the frontal sinus opening. Laryngoscope. 2016;126(12):2659-2664.
87.
NarwaniVTorabiSJKasleDAPatelRALernerMZManesRP. Adverse events associated with corticosteroid-eluting sinus stents: a MAUDE database analysis. Otolaryngol Head Neck Surg. Published online April 13, 2021. doi:10.1177/01945998211006930
88.
MillerLEBhattacharyyaN. Risk of COVID-19 infection among chronic rhinosinusitis patients receiving oral corticosteroids. Otolaryngol Head Neck Surg. Published online April 13, 2021. doi:10.1177/01945998211006931
89.
HarveyRJSnidvongsKKalishLHOakleyGMSacksR. Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018;8(4):461-470.
90.
KuanECKovacsAJWorkmanADBossoJVAdappaND. Efficacy of fluticasone exhalation delivery system in the management of chronic rhinosinusitis: what is the evidence?Int Forum Allergy Rhinol. 2019;9(S1):S16-S21.
91.
ParselSMMohammedAEFortDBartonBMMcCoulED. Intramuscular corticosteroids for acute upper respiratory infections affects healthcare utilization. Ann Otol Rhinol Laryngol. 2020;129(10):988-995.
92.
ParselSMMcCoulED. Corticosteroid utilization among otolaryngologists for the treatment of acute upper respiratory tract infections. Am J Otolaryngol. 2021;42(4):102930.
93.
DvorinELRothbergMBRoodMNMartinezKA. Corticosteroid use for acute respiratory tract infections in direct-to-consumer telemedicine. Am J Med. 2020;133(8):e399-e405.
94.
D’AscanioLPandolfiniMCingolaniC, et al. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg. 2021;164(1):82-86.
95.
GoshtasbiKPangJLehrichBM, et al. Association between olfactory dysfunction and critical illness and mortality in COVID-19: a meta-analysis. Otolaryngol Head Neck Surg. Published online May 25, 2021. doi:10.1177/01945998211017442
LiuKYuZ. The association between olfactory/gustatory dysfunction and the course of infection is still not demonstrated. Otolaryngol Head Neck Surg. Published online February 9, 2021. doi:10.1177/0194599821994837
98.
PadernoAMattavelliDPiazzaC. Long-term olfactory and gustatory dysfunction may be related to neural damage. Otolaryngol Head Neck Surg. Published online February 9, 2021. doi:10.1177/0194599821994845
99.
SaniasiayaJIslamMAAbdullahB. Prevalence and characteristics of taste disorders in cases of COVID-19: a meta-analysis of 29,349 patients. Otolaryngol Head Neck Surg. 2021;165(1):33-42.
100.
D’AscanioLVitelliFCingolaniCMaranzanoMBrennerMJDi StadioA. Randomized clinical trial “olfactory dysfunction after COVID-19: olfactory rehabilitation therapy vs intervention treatment with palmitoylethanolamide and luteolin”: preliminary results. Eur Rev Med Pharmacol Sci. 2021;25(11):4156-4162.
101.
LevyJM. Treatment recommendations for persistent smell and taste dysfunction following COVID-19—the coming deluge. JAMA Otolaryngol Head Neck Surg. 2020;146(8):733.
102.
SorokowskaADrechslerEKarwowskiMHummelT. Effects of olfactory training: a meta-analysis. Rhinology. 2017;55(1):17-26.
103.
KattarNDoTMUnisGDMigneronMRThomasAJMcCoulED. Olfactory training for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2021;164(2):244-254.
104.
JangSSChoiJSKimJHKimNFerenceEH. Discordance between subjective and objective measures of smell and taste in US adults. Otolaryngol Head Neck Surg. Published online June 22, 2021. doi:10.1177/01945998211018386
105.
HustonMNNaunheimMR. Acute laryngeal injury after intubation—does wait and see mean wait and scar?JAMA Otolaryngol Head Neck Surg. 2021;147(3):237-238.
106.
SmithJDChenMMBalakrishnanK, et al. The difficult airway and aerosol-generating procedures in COVID-19: timeless principles for uncertain times. Otolaryngol Head Neck Surg. 2020;163(5):934-937.
107.
RoySCramerJDBier-LaningCPalmieriPARassekhCHBrennerMJ. Emergency surgical airway algorithm for difficult airway management during the COVID-19 pandemic. Otolaryngol Head Neck Surg. 2021;165(1):235-236.
108.
PrinceADPCloydBHHogikyanNDSchechtmanSAKupferRA. Airway management for endoscopic laryngotracheal stenosis surgery during COVID-19. Otolaryngol Head Neck Surg. 2020;163(1):78-80.
109.
CramerJDBrennerMJFeller-KopmanD. Acute upper airway obstruction. N Engl J Med. 2020;382(8):783.
110.
BalakrishnanKBrennerMJHillelAT. Laryngeal and tracheal pressure injuries in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021;147(5):484-485.
111.
SnowGEShaverTBTeplitzkyTBGuardianiE. Predictors of tracheostomy decannulation in adult laryngotracheal stenosis. Otolaryngol Head Neck Surg. 2021;164(6):1265-1271.
112.
DwyerCDQiabiMFortinD, et al. Idiopathic subglottic stenosis: an institutional review of outcomes with a multimodality surgical approach. Otolaryngol Head Neck Surg. 2021;164(5):1068-1076.
113.
GatesAGatesMVandermeerB, et al. Glucocorticoids for croup in children. Cochrane Database Syst Rev. 2018;8:CD001955.
114.
RiffatFJeffersonNBariNMcGuinnessJ. Acute supraglottitis in adults. Ann Otol Rhinol Laryngol. 2011;120(5):296-299.
115.
Solans-LaqueRBosch-GilJCanelaMLorenteJPallisaEVilardell-TarresM. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Lupus. 2008;17(9):832-836.
116.
SongSAFrancoRAJr. Serial intralesional steroid injection for subglottic stenosis. Laryngoscope. 2020;130(3):698-701.
117.
FrancoRAJrHusainIRederLPaddleP. Awake serial intralesional steroid injections without surgery as a novel targeted treatment for idiopathic subglottic stenosis. Laryngoscope. 2018;128(3):610-617.
118.
HoffmanMRCoughlinARDaileySH. Serial office-based steroid injections for treatment of idiopathic subglottic stenosis. Laryngoscope. 2017;127(11):2475-2481.
119.
WolianskyJPhylandDPaddleP. Systemic safety of serial intralesional steroid injection for subglottic stenosis. Laryngoscope. 2019;129(7):1634-1639.
120.
DavisRJLinaIMotzK, et al. Endoscopic resection and mucosal reconstitution with epidermal grafting: a pilot study in idiopathic subglottic stenosis. Otolaryngol Head Neck Surg. Published online July 13, 2021. doi:10.1177/01945998211028163
121.
AlrabiahAAlsayedAAljasserA, et al. Effect of inhaled fluticasone propionate on laryngotracheal stenosis after balloon dilation: a randomized controlled trial. Eur Arch Otorhinolaryngol. 2021;278(5):1505-1513.
122.
YokoiANakaoMBitohYAraiHOshimaYNishijimaE. Treatment of postoperative tracheal granulation tissue with inhaled budesonide in congenital tracheal stenosis. J Pediatr Surg. 2014;49(2):293-295.
123.
MasoliMWeatherallMHoltSShirtcliffePBeasleyR. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28(5):960-967.
124.
ChoiJCJungSYYoonUA, et al. Inhaled corticosteroids and COVID-19 risk and mortality: a nationwide cohort study. J Clin Med. 2020;9(11):3406.
125.
KowCSHasanSS. Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: a meta-analysis. J Asthma. Published online February 8, 2021. doi:10.1080/02770903.2021.1878531
126.
GovilNRafiiBYPaulBCRuizRAminMRBranskiRC. Glucocorticoids for vocal fold disease: a survey of otolaryngologists. J Voice. 2014;28(1):82-87.
127.
AminMRAchlatisSGhersonS, et al. The role of oral steroids in the treatment of phonotraumatic vocal fold lesions in women. Otolaryngol Head Neck Surg. 2019;160(3):512-518.
128.
WangCTLaiMSChengPW. Long-term surveillance following intralesional steroid injection for benign vocal fold lesions. JAMA Otolaryngol Head Neck Surg. 2017;143(6):589-594.
129.
WangCTLiaoLJChengPWLoWCLaiMS. Intralesional steroid injection for benign vocal fold disorders: a systematic review and meta-analysis. Laryngoscope. 2013;123(1):197-203.
130.
HillelATLinLMSamlanRStarmerHLeahyKFlintPW. Inhaled triamcinolone with proton pump inhibitor for treatment of vocal process granulomas: a series of 67 granulomas. Ann Otol Rhinol Laryngol. 2010;119(5):325-330.
131.
AllenDB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol. 2000;106(4):S179-S190.
132.
CelebiOOSongSASanteerapharpAChoksawadKFrancoRAJr. Assessment of side effects after serial intralesional steroid injections for idiopathic subglottic stenosis. Eur Arch Otorhinolaryngol. 2021;278(2):445-450.
133.
EdsbackerSJohanssonCJ. Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Toxicol. 2006;98(6):523-536.
134.
GulliverTEidN. Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am. 2005;25(3):541-555.
135.
SampieriGNamavarianALeeJJWHamourAFLeeJM. Hypothalamic-pituitary-adrenal axis suppression and intranasal corticosteroid use: a systematic review and meta-analysis. Int Forum Allergy Rhinol. Published online July 14, 2021. doi:10.1002/alr.22863
136.
VargasRDockhornRJFindlaySRKorenblatPEFieldEAKralKM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102(2):191-197.
137.
AvivJEChandrasekharSThomashowB. COVID-19 era post viral vagal neuropathy presenting as persistent shortness of breath with normal pulmonary imaging. Int J Pul Res Sci. 2020;4(4):555641. doi:10.19080/IJOPRS.2020.04.555641
138.
KawashitaYFunaharaMYoshimatsuM, et al. A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer: is topical steroid therapy a risk factor for oral candidiasis?Medicine (Baltimore). 2018;97(44):e13073.
139.
KawashitaYSoutomeSUmedaMSaitoT. Oral management strategies for radiotherapy of head and neck cancer. Jpn Dent Sci Rev. 2020;56(1):62-67.
140.
LamTCWongFCLeungTWNgSHTungSY. Clinical outcomes of 174 nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. Int J Radiat Oncol Biol Phys. 2012;82(1):e57-e65.
141.
LeborgneJHLeborgneFZubizarretaEOrtegaBMezzeraJ. Corticosteroids and radiation mucositis in head and neck cancer: a double-blind placebo-controlled randomized trial. Radiother Oncol. 1998;47(2):145-148.
142.
WagenblastJArnoldnerCGstottnerW, et al. Does dexamethasone inhibit the antineoplastic effect of cisplatin and docetaxel in head and neck cancer cells?Anticancer Res. 2010;30(1):123-127.
143.
ZendaSYamaguchiTYokotaT, et al. Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. BMC Cancer. 2018;18(1):873.
144.
ClayburghDStottWBolognoneR, et al. A randomized controlled trial of corticosteroids for pain after transoral robotic surgery. Laryngoscope. 2017;127(11):2558-2564.
145.
KainulainenSLassusPSuominenAL, et al. More harm than benefit of perioperative dexamethasone on recovery following reconstructive head and neck cancer surgery: a prospective double-blind randomized trial. J Oral Maxillofac Surg. 2018;76(11):2425-2432.
146.
KainulainenSTornwallJKoivusaloAMSuominenALLassusP. Dexamethasone in head and neck cancer patients with microvascular reconstruction: no benefit, more complications. Oral Oncol. 2017;65:45-50.
147.
OostingSFHaddadRI. Best practice in systemic therapy for head and neck squamous cell carcinoma. Front Oncol. 2019;9:815.
148.
DortJCFarwellDGFindlayM, et al. Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society. JAMA Otolaryngol Head Neck Surg. 2017;143(3):292-303.
149.
ImaiTKurosawaKAsadaY, et al. Enhanced recovery after surgery program involving preoperative dexamethasone administration for head and neck surgery with free tissue transfer reconstruction: single-center prospective observational study. Surg Oncol. 2020;34:197-205.
CuriglianoGBanerjeeSCervantesA, et al. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol. 2020;31(10):1320-1335.
152.
ChangJSunwooJBShahJL, et al. Association between immunosuppression and outcomes in oral cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2021;164(5):1044-1051.
153.
GraboyesECramerJBalakrishnanK, et al. COVID-19 pandemic and health care disparities in head and neck cancer: scanning the horizon. Head Neck. 2020;42(7):1555-1559.
154.
ThompsonJALubekJEAminN, et al. Impact of the novel coronavirus 2019 (COVID-19) pandemic on head and neck cancer care. Otolaryngol Head Neck Surg. Published online March 30, 2021. doi:10.1177/01945998211004544
155.
CocksHAh-SeeKCapelMTaylorP. Palliative and supportive care in head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S198-S207.
156.
ElsayemABrueraE. High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway. Support Care Cancer. 2007;15(12):1437-1439.
157.
RaggioBSWintersRD. Role of steroids in preventing osteoradionecrosis of the head and neck: a systematic review. Ann Otol Rhinol Laryngol. 2019;128(5):441-446.
158.
YokotaTZendaSOtaI, et al. Phase 3 randomized trial of topical steroid versus placebo for prevention of radiation dermatitis in patients with head and neck cancer receiving chemoradiation. Int J Radiat Oncol Biol Phys. 2021;111(3):794-803.
159.
MehtaVGoelSKabarritiR, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020;10(7):935-941.
160.
HannaGJRettigEMParkJC, et al. Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021;112:105087.
161.
KudererNMChoueiriTKShahDP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.
162.
DesaiAGainorJFHegdeA, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021;18(5):313-319.
Osazuwa-PetersNGraboyesEMKhariwalaSS. Expanding indications for the human papillomavirus vaccine: one small step for the prevention of head and neck cancer, but one giant leap remains. JAMA Otolaryngol Head Neck Surg. 2020;146(12):1099-1101.
165.
BellmuntAMVilaPMChenJXRosenfeldRMHackellJMShinJJ. Oral steroid usage for otitis media with effusion, eustachian tube dysfunction, and tympanic membrane retraction. Otolaryngol Head Neck Surg. 2016;155(1):139-146.
166.
MehtaNKMaCNguyenSAMcRackanTRMeyerTALambertPR. Medical management for eustachian tube dysfunction in adults: a systematic review and meta-analysis. Laryngoscope. Published online October 4, 2021. doi:10.1002/lary.29878
167.
BrottoDSorrentinoFFavarettoNBovoRTrevisiPMartiniA. Pediatric hearing loss management in the COVID-19 era: possible consequences and resources for the next future. Otolaryngol Head Neck Surg. Published online May 4, 2021. doi:10.1177/01945998211012677
168.
DiercksGRCohenMS. The effect of the COVID-19 pandemic on pediatric tympanostomy tube placement. Otolaryngol Head Neck Surg. Published online May 4, 2021. doi:10.1177/01945998211008916
169.
BannDVPatelVASaadiR, et al. Best practice recommendations for pediatric otolaryngology during the COVID-19 pandemic. Otolaryngol Head Neck Surg. 2020;162(6):783-794.
170.
StonerMJDulaurierM. Pediatric ENT emergencies. Emerg Med Clin North Am. 2013;31(3):795-808.
171.
SmithDFde AlarconAJeffersonND, et al. Short- versus long-term stenting in children with subglottic stenosis undergoing laryngotracheal reconstruction. Otolaryngol Head Neck Surg. 2018;158(2):375-380.
172.
CzarnetzkiCEliaNLysakowskiC, et al. Dexamethasone and risk of nausea and vomiting and postoperative bleeding after tonsillectomy in children: a randomized trial. JAMA. 2008;300(22):2621-2630.
173.
RedmannAJMaksimoskiMBrumbaughCIshmanSL. The effect of postoperative steroids on post-tonsillectomy pain and need for postoperative physician contact. Laryngoscope. 2018;128(9):2187-2192.
TitirungruangCSeresirikachornKKasemsuwanPHirunwiwatkulP. The use of steroids to reduce complications after tonsillectomy: a systematic review and meta-analysis of randomized controlled studies. Eur Arch Otorhinolaryngol. 2019;276(2):585-604.
176.
Kheirandish-GozalLBhattacharjeeRBandlaHPRGozalD. Antiinflammatory therapy outcomes for mild OSA in children. Chest. 2014;146(1):88-95.
177.
KomshianSRCohenMBBrookCLeviJR. Inferior turbinate hypertrophy: a review of the evolution of management in children. Am J Rhinol Allergy. 2019;33(2):212-219.
SobolSESamadiDSKazahayaKTomLW. Trends in the management of pediatric chronic sinusitis: survey of the American Society of Pediatric Otolaryngology. Laryngoscope. 2005;115(1):78-80.
180.
MercierEDombrowskiNRahbarR, et al. IPOG COVID-19 Report—April 14th 2020. International Pediatric Otolaryngology Group; 2020.
Pfizer. A phase 1/2/3, placebo-controlled randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals. Accessed January 17, 2021. https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol.pdf
Pfizer. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed January 16, 2021. http://labeling.pfizer.com/ShowLabeling.aspx?id=14471
187.
Moderna. Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Accessed January 16, 2021. https://www.modernatx.com/COVID19vaccine-eua/eua-fact-sheet-providers.pdf
Centers of Disease Control and Prevention. Altered immunocompetence general best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Updated November 25, 2021. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
192.
LiuDAhmetAWardL, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
SchmalbachCEBreretonJBowmanCDennenyJC3rd. American Academy of Otolaryngology–Head and Neck Surgery/Foundation Reg-ent registry: purpose, properties, and priorities. Otolaryngol Head Neck Surg. 2021;164(5):964-971.
195.
MichelJJSchwartzSRDawsonDE, et al. Quality improvement in otolaryngology–head and neck surgery: developing registry-enabled quality measures from guidelines for cerumen impaction and allergic rhinitis through a transparent and systematic process. Otolaryngol Head Neck Surg. Published online May 18, 2021. doi:10.1177/01945998211011987
196.
NaunheimMRRandolphGWShinJJ. Evidence-based medicine in otolaryngology part XII: assessing patient preferences. Otolaryngol Head Neck Surg. 2021;164(3):473-481.
197.
FornerDNoelCWDensmoreR, et al. Shared decision making for surgical care in the era of COVID-19. Otolaryngol Head Neck Surg. 2021;164(2):297-299.
198.
CramerJDBalakrishnanKRoyS, et al. Intraoperative sentinel events in the era of surgical safety checklists: results of a national survey. OTO Open. 2020;4(4):2473974X20975731.
199.
BrennerMJChangCWDBossEFGoldmanJLRosenfeldRMSchmalbachCE. Patient safety/quality improvement primer, part I: what PS/QI means to your otolaryngology practice. Otolaryngol Head Neck Surg. 2018;159(1):3-10.
200.
BalakrishnanKBrennerMJGosbeeJWSchmalbachCE. Patient safety/quality improvement primer, part II: prevention of harm through root cause analysis and action (RCA(2)). Otolaryngol Head Neck Surg. 2019;161(6):911-921.
SadoffJLe GarsMShukarevG, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine. N Engl J Med. 2021;384(19):1824-1835.
203.
VoyseyMClemensSACMadhiSA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
